Gregory A. Prince, 1 Amy Mathews, 1 Spencer J. Curtis, 1 and David D. Porter 2
|
|
- Helena Shaw
- 6 years ago
- Views:
Transcription
1 1326 Treatment of Respiratory Syncytial Virus Bronchiolitis and Pneumonia in a Cotton Rat Model with Systemically Administered Monoclonal Antibody (Palivizumab) and Glucocorticosteroid Gregory A. Prince, 1 Amy Mathews, 1 Spencer J. Curtis, 1 and David D. Porter 2 1 Virion Systems, Rockville, Maryland; 2 Department of Pathology and Laboratory Medicine, School of Medicine, University of California, Los Angeles Parenteral treatment of an experimental respiratory syncytial virus (RSV) infection in a cotton rat model with a monoclonal antibody directed against the viral F protein resulted in the clearance of infectious virus within 24 h but had no effect on the pulmonary pathology at 24 h and only a small effect on the pulmonary pathology at 72 h. Treatment with parenteral triamcinolone acetonide dramatically reduced the pathologic lesions of viral bronchiolitis and pneumonia but resulted in the delayed clearance of the virus. The combination of the monoclonal antibody given in a single dose 72 h after infection, combined with 3 daily doses of the corticosteroid starting 72 h after infection, demonstrated both the loss of infectivity and the disappearance of lesions. No rebound of lesions or infectivity was noted. Combined antiviral and anti-inflammatory therapy for RSV disease appears promising. Respiratory syncytial virus (RSV), the leading cause of infectious pulmonary disease in infants and children worldwide (reviewed in [1]), is increasingly recognized as a cause of serious disease in adults, particularly the elderly [2] and in immunocompromised persons [3]. Vaccine development programs spanning 4 decades have yet to result in a safe and effective RSV vaccine [4]. A major breakthrough in RSV prophylaxis has been the development and licensure both of polyclonal and monoclonal immunoglobulin products for use in high-risk infants (RespiGam [RSVIg] and Synagis [palivizumab]; MedImmune, Gaithersburg, MD). Although highly effective and apparently cost-effective in the targeted population, these products have not been widely used in persons at normal risk owing to the cost. Since most hospital admissions for RSV are among normal-risk patients, there is a pressing need for an effective RSV therapeutic [5]. More than a decade has elapsed since the licensure by the US Food and Drug Administration (FDA) of ribavirin (Virazole; ICN Pharmaceuticals, Costa Mesa, CA) as an RSV therapeutic. Initial enthusiasm for this drug, however, has gradually been replaced by increasing resistance to its use, as concerns over efficacy, cost, and ease of use have grown [6]. The use of RSV immunoglobulin in a therapeutic setting was first suggested in studies in cotton rats. Immunoglobulin given to RSV-infected animals reduced pulmonary virus titers 100- Received 23 June 2000; revised 28 July 2000; electronically published 9 October Financial support: National Institutes of Health (AI-33722); Virion Systems corporate funds. Reprints or correspondence: Dr. Gregory A. Prince, Virion Systems, 9610 Medical Center Dr., Ste. 100, Rockville, MD (gprince@erols.com). The Journal of Infectious Diseases 2000;182: by the Infectious Diseases Society of America. All rights reserved /2000/ $02.00 fold within 6 h [7], a level of reduction far greater than that seen with ribavirin in the same animal model [8]. This observation led to a series of therapeutic clinical trials of RSV immunoglobulin formulations, including generic human IgG given parenterally [9] or via aerosol [10, 11], RSVIg given parenterally [12, 13], and palivizumab given parenterally [14]. Although these studies showed immunoglobulin therapy to be safe, thus overturning a long-standing dogma [15], and monitored virus titers showed a reduction in immunoglobulintreated patients, none resulted in a clinically beneficial outcome. Although the goal of the clinician in treating an infectious disease has long been the elimination of the pathogen, there has been a recent and increasing awareness of the need to simultaneously treat the consequences of infection, which often consist of the host response to infection rather than to the direct tissue damage by the pathogen. We reported earlier that an antiviral immunoglobulin and a glucocorticosteroid delivered topically were highly effective in eliminating virus and reversing pulmonary histopathology in a cotton rat model of human parainfluenza virus type 3 (PIV3) [16]. We now extend these findings to treatment of RSV bronchiolitis and pneumonia, using an antiviral monoclonal antibody and a glucocorticosteroid delivered systemically. Materials and Methods Animals. Inbred cotton rats (Sigmodon hispidus) were obtained from a colony maintained at Virion Systems (Rockville, MD). The cotton rats were housed in large polycarbonate rat cages with a bedding of paper mill by-products (Care Fresh; Absorption, Bellingham, WA) and were fed a diet of rodent chow and water. The cotton rat colony was monitored for antibody to paramyxoviruses, RSV, and rodent viruses, and no such antibodies were
2 JID 2000;182 (November) Treatment of Bronchiolitis and Pneumonia 1327 found. The animals were, on average, 5 weeks old and weighed 60 g at the time of use. Viruses and cells. The prototype Long strain of RSV (American Type Culture Collection, Manassas, VA) was propagated in HEp-2 cells after serial plaque-purification, to reduce defectiveinterfering particles [17]. A single pool of virus containing pfu/ ml was used for all experiments. Pulmonary virus titers were determined by plaque assay, as described elsewhere [18]. Drugs. Palivizumab (Synagis), a humanized monoclonal antibody directed against the F glycoprotein of RSV [19], was provided by MedImmune. Triamcinolone acetonide suspension, United States Pharmacopeia, was manufactured by Steris Laboratories (Phoenix). Methoxyflurane for anesthesia was obtained from Pitman-Moore (Mundelein, IL). Tissue preparation. After the animals were killed by carbon dioxide inhalation, the heart and lungs were removed together from the cotton rats. The 2 left lobes of the lungs were ligated around the bronchi and then were removed for virus quantitation. The 3 right lobes were then inflated through the trachea to their normal volume with 10% neutral buffered formalin. The trachea was tied with a suture, and the lungs were immersed in formalin for several days. A block was cut in a coronal orientation to show the hilar and peripheral areas of the 3 lobes on a single slide. After paraffin embedding, sections were cut at a thickness of 4 mm and were stained with hematoxylin-eosin. Histopathology scoring. Peribronchiolitis is inflammatory cells, mostly lymphocytes and macrophages, that accumulate around the periphery of small airways. Alveolitis is inflammatory cells, mostly macrophages and neutrophils, within the air spaces. Interstitial pneumonitis is thickening of the alveolar walls, associated with an influx of inflammatory cells of various types. Each of these 3 parameters was scored separately for each lung section on a scale of 0 (no inflammation) to 100 (maximum inflammation). Composite scores were also determined by calculating the arithmetic mean of the 3 individual scores for each lung section. Both the magnitude and the profile of inflammation were different in these experiments than in those that we reported because of the markedly higher dose of virus that each animal received. Experimental design. Cotton rats were anesthetized with methoxyflurane and then were inoculated intranasally with 100 ml of virus suspension: pfu per animal. Three days thereafter, at the time of peak viral replication, animals were given a single intramuscular (im) injection of palivizumab (15 mg/kg). Animals receiving glucocorticosteroid were given varying im doses of triamcinolone acetonide daily beginning 3 days after challenge. Statistical analysis. Virus titers were expressed as the geometric mean SE for all animals in a group at a given time. Pulmonary parameters were expressed as the arithmetic mean SE. The 2-tailed Student s t test, using summary data, was used to determine the significance of differences between groups. Statistical analysis of composite histology scores was not done, since the data are disparate. days after infection (figure 1, group 2). A single dose of palivizumab on day 3 (figure 1, group 3) reduced virus titers fold to undetectable levels within 1 day. Despite the dramatic clearance of virus, however, palivizumab-treated animals had little improvement in pulmonary lesions (figure 2, group 3; P 1.05 on day 4; P!.05 on day 6 vs. untreated animals in group 2), as shown photographically for this and subsequent treatments in figure 3. A similar lack of or only a small effect of antibody alone was seen for alveolitis and interstitial pneumonitis (data not shown). This parallels our findings with PIV3 [16] and is consistent with the clinical trials alluded to, in which virus titers were reduced, and clinical trends were in a positive direction but without statistical significance. Triamcinolone treatment without palivizumab. The immunosuppressive effect of glucocorticosteroids is well documented and is the basis for the longstanding dogma of not using such drugs without antimicrobial coverage in patients with an infectious disease. In the current experiments, triamcinolone significantly ( P!.001 for groups 4 and 5) delayed viral clearance in a dosedependent manner (figure 1), with the highest dose resulting in the greatest impairment of clearance. However, unlike the previous experiments with PIV3 [16], the yield of RSV did not exceed that of untreated cotton rats either at 4 or 6 days after infection. Results Palivizumab treatment without triamcinolone. Infected, untreated animals developed pulmonary virus titers of 10 6 pfu/g 4 Figure 1. Comparison of respiratory syncytial virus (RSV) lung titers 4 and 6 days after infection by treatment group (9 12 animals per day per treatment group). Significant at P!.001 (*) or at P!.05 (#), compared with infected but untreated animals. Bars are SE; im, intramuscularly.
3 1328 Prince et al. JID 2000;182 (November) Figure 2. Peribronchiolitis scores by treatment group at 4 and 6 days after infection with respiratory syncytial virus (RSV; 9 12 animals per day per treatment group). Significant at P!.001 (*), P!.02 ( ), or P!.05(#), compared with infected but untreated animals. Bars are SE; im, intramuscularly. All 3 groups treated with triamcinolone alone had accelerated clearance of peribronchiolitis (figure 2, groups 4 6). The most dramatic improvement was in animals receiving the highest dose of triamcinolone ( P!.001 vs. group 4, with either group 2 or 3 on both days 4 and 6). Treatment with palivizumab plus triamcinolone. As we reported elsewhere regarding PIV3 pneumonia [16], cotreatment with an antiviral antibody and a glucocorticosteroid accelerated the clearance of virus at the same time that it reversed the histopathologic changes in the lungs. There was a steep steroid dose-effectiveness curve: a dose of 16 mg/kg/day (days 3 5) resulted in a highly significant improvement in peribronchiolitis (figure 2, group 7; P!.001 vs. group 2, days 4 and 6), whereas a 4-fold lower dose was effective only on day 6 (figure 2, group 8). As with other treatment modes, the patterns for alveolitis and interstitial pneumonitis were essentially the same as those for peribronchiolitis (data not shown). Is there a rebound effect? In our prior report on PIV3, we showed that animals cotreated with antibody and triamcinolone remained free of virus after cessation of therapy on day 5 but experienced a reappearance of pulmonary histopathology that approached, but did not exceed, that of infected but untreated animals [16]. Prolongation of triamcinolone therapy in that study for an additional 3 days eliminated the rebound effect. To test for the possibility of rebound in the current experimental system, we infected and treated animals as in the above experiments, administering palivizumab on day 3 and triamcinolone on days 3 5. Animals were killed at 2-day intervals through postchallenge day 14. Figure 4 demonstrates that, unlike our prior work with PIV3, there is no rebound of histopathology in RSV-infected cotton rats that were cotreated with palivizumab and triamcinolone. This figure also shows that palivizumab alone has little effect on pulmonary histopathology, which is present, even if minimal, through day 14. Effect of rechallenge. Although combined therapy of RSV infection appears to be safe, the effect of therapy on subsequent RSV infection is an issue that, in light of the failed vaccine trials of the 1960s, must be addressed. In other words, does combined therapy cause an altered immune status that results in enhanced RSV disease later? We examined this possibility by infecting cotton rats with RSV, treating them with palivizumab and triamcinolone, and then rechallenging them 3 weeks later, as we did elsewhere [16], with PIV3. The results of this experiment paralleled those of the PIV3 report, namely, that animals previously infected with RSV and given combined therapy had no evidence of enhanced histopathology after rechallenge. Indeed, as in the earlier report, these animals showed milder histologic changes than did animals undergoing either primary or secondary RSV infection (data not shown). Discussion Both the medical and the economic importance of RSV are attested to by the extensive array of candidate antiviral compounds under development [20]. The current expense of passive prophylaxis, the difficulties spanning 4 decades with vaccine development, and the likelihood that many patients will not respond to vaccination ensure the need for RSV therapies into the indefinite future. The development of such therapies, however, has been hampered by 2 factors. The first has been the difficulty in formulating an RSV antiviral that is highly effective, nontoxic, and easily administered. This difficulty appears to have been overcome by the development of palivizumab. The second factor has been the failure of any RSV antiviral compound to modulate the host inflammatory response to RSV infection, which appears to account for most of the disease manifestation. The lack of clinical efficacy of RSV immunoglobulins, either polyclonal or monoclonal, despite their acceleration of viral clearance, strongly endorses the hypothesis that an effective therapeutic regimen must down-regulate the host inflammatory response, in addition to eliminating the virus. Our prior reports documented the ability of such a combined approach to reverse pulmonary disease caused by human PIV3 and by RSV in the cotton rat model, when the antiviral component was polyclonal immunoglobulin and the combined formulation was administered intranasally [16, 21]. Although we still see the potential value in a topically administered formu-
4 JID 2000;182 (November) Treatment of Bronchiolitis and Pneumonia 1329 Figure 3. Lung histology in cotton rats infected with respiratory syncytial virus (RSV) 6 days earlier. Bronchiole is shown in each frame. A, Uninfected and untreated animals; B, infected and untreated animals; C, infected and treated with monoclonal antibody only animals; D, infected and treated with both monoclonal antibody and triamcinolone animals. Infected but untreated animals had severe peribronchiolitis, interstitial pneumonitis, and alveolitis. Treatment with monoclonal antibody alone had little to no effect on intensity of the lesions. Treatment with triamcinolone together with monoclonal antibody abolished the peribronchiolitis and markedly reduced the interstitial pneumonitis and alveolitis. Hematoxylineosin stain; original magnification, 120. lation, logistic considerations that involves the stability of a combined formulation and the practicality of a delivery system adaptable to infants will probably delay clinical testing and implementation of such an approach. In the meantime, an impressive track record of systemic RSV prophylaxis with the use of palivizumab has been achieved. Unlike its first-generation predecessor, RSVIg, which required intravenous infusion over several hours, palivizumab is administered within seconds via intramuscular injection. Similarly, glucocorticosteroids have an extensive track record of efficacy, safety, and simple administration via parenteral injection. Thus, the methodology described in the current report has logistic advantages of employing 2 drugs that are already licensed by the FDA and administering them in a manner already widely used. Our findings in the current study parallel those in our earlier work on PIV3 in all of the essential elements. First, they demonstrate that palivizumab, although highly effective in eliminating RSV from the experimental host, had no significant effect on pulmonary histopathology, which we consider to be the best surrogate of clinical disease in the cotton rat model. Second, we again showed that glucocorticosteroids, used alone, have a beneficial effect on pulmonary histopathology but at the expense of impaired virus clearance. Such a situation is of unknown, but potential, detriment to the patient and represents an undesirable increased risk of nosocomial spread of RSV, already a major concern in pediatric hospital settings. By combining antiviral and anti-inflammatory drugs, however, we have achieved reversal of pulmonary histopathology while, at the Figure 4. Composite pathology scores 4 14 days after respiratory syncytial virus (RSV) infection by treatment group. Nos. of animals in group are at tops of bars. Statistical evaluation was not performed on these data because of their disparate nature. MAb, monoclonal antibody. Tri, triamcinolone.
5 1330 Prince et al. JID 2000;182 (November) same time, overcoming the immunosuppressive effect of the glucocorticosteroid. The one point of departure of the current study from our earlier work with PIV3 is the lack of a rebound effect with RSV. It is not clear whether this is due to the different pathogen, the different potency of the antiviral immunoglobulin (monoclonal vs. polyclonal), or the different mode of administration (systemic vs. topical) of both components. Nonetheless, the lack of rebound found in the current study is encouraging, since it suggests that clinical use of the glucocorticosteroid can be limited to a period that will not result in suppression of adrenal function. The selection of triamcinolone acetonide as the anti-inflammatory component was based on our earlier screening of a variety of commonly used glucocorticosteroids [16, 21], which showed triamcinolone to be the most effective when used topically. Systemic use of triamcinolone in a pediatric setting, however, is not common and may be greeted with reluctance by some clinicians. Therefore, we have undertaken a study in which we are comparing triamcinolone with 2 other glucocorticosteroids that are commonly administered systemically by pediatricians, methyl prednisolone and dexamethasone. That study will form the basis of a separate report. References 1. Collins PL, McIntosh K, Chanock RM. Respiratory syncytial virus. In: Fields BN, Knipe DM, Howley PM, et al. Fields virology. 3d ed. Vol. 1. Philadelphia: Lippincott-Raven, 1996: Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 1999; 179: McCarthy AJ, Kingman HM, Kelly C, et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation. Bone Marrow Transplant 1999;24: Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev 1998;11: Domachowske JB, Rosenberg HF. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin Microbiol Rev 1999;12: Ohmit SE, Moler FW, Monto AS, Khan AS. Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection. J Clin Epidemiol 1996;49: Prince GA, Hemming VG, Horswood RL, Chanock RM. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res 1985;3: Hruska JF, Morrow PE, Suffin SC, Douglas RG. In vivo inhibition of respiratory syncytial virus by ribavirin. Antimicrob Agents Chemother 1982; 21: Hemming VG, Rodriguez W, Kim HW, et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob Agents Chemother 1987;31: Rimensberger PC, Schaad UB. Clinical experience with aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. Pediatr Infect Dis J 1994;13: Rimensberger PC, Burek-Kozlowska A, Morell A, et al. Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. Pediatr Infect Dis J 1996;15: Rodriguez, WJ, Gruber WC, Welliver RC, et al. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections. Pediatrics 1997;99: Rodriguez WJ, Gruber WC, Groothuis JR, et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 1997;100: Malley R, DeVincenzo J, Ramilo O, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998;178: Chanock RM, Kapikian AZ, Mills J, Kim HW, Parrott RH. Influence of immunological factors in respiratory syncytial virus disease of the lower respiratory tract. Arch Environ Health 1970;21: Prince GA, Porter DD. Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid. J Infect Dis 1996;173: Gupta CK, Leszczynski J, Gupta RK, Siber GR. Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. Vaccine 1996;14: Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 1978;93: Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997;176: Prince GA. Respiratory syncytial virus antiviral agents. Exp Opin Ther Patents 1999;9: Prince GA, Hemming VG. Method for treating infectious respiratory diseases. US patent 5,290,540, 1994.
NOTES. for histology. The remainder of each organ was. weighed, diluted 1:10 in Hanks balanced salt. solution, homogenized, and centrifuged for 5
NFECTON AND MMUNTY, JUlY 1982, p. 369-373 0019-9567/82/070369-05$02.00/0 Vol. 37. No. 1 NOTES Respiratory Syncytial Virus nfection in Cyclophosphamide- Treated Cotton Rats RODNEY A. JOHNSON, GREGORY A.
More informationDisclosures. Learning Objectives. Modification of RSV Prophylaxis Recommendations in the 2009 Red Book Why Was it Done, and What Does it Mean for You?
Modification of RSV Prophylaxis Recommendations in the 2009 Red Book Why Was it Done, and What Does it Mean for You? David W. Kimberlin, M.D. Disclosures I have no actual or potential conflict of interest
More information(Accepted 20 April 1989)
J. gen. Virol. (1989), 7, 2185-219. Printed in Great Britain 2185 Key words: RSV/vaccinia virus/antibody-mediated immune suppression Immunosuppression of the Antibody Response to Respiratory Syncytial
More informationWake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection
Wake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection General Information Aerosolized ribavirin has been shown in limited clinical
More informationWake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection
Wake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection General Information Aerosolized ribavirin has been shown in limited clinical
More informationClinical Policy: Palivizumab (Synagis) Reference Number: ERX.SPA.124 Effective Date: Last Review Date: 08.17
Clinical Policy: (Synagis) Reference Number: ERX.SPA.124 Effective Date: 10.01.16 Last Review Date: 08.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPassive vaccination as a global strategy for preventing RSV disease in infants. Filip Dubovsky MD MPH FAAP MedImmune March 2016
Passive vaccination as a global strategy for preventing RSV disease in infants Filip Dubovsky MD MPH FAAP MedImmune March 2016 Outline for Presentation Rationale for passive immunization for RSV prophylaxis
More informationRespiratory Syncytial Virus (RSV) Just another virus or not? Doris Makari, MD Senior Director, Scientific Affairs Nov 16th, 2012
Respiratory Syncytial Virus (RSV) Just another virus or not? Doris Makari, MD Senior Director, Scientific Affairs Nov 16th, 2012 Key Points RSV is not just another virus to infants RSV is the leading cause
More informationDrug Utilization Review: Palivizumab (Synagis ; Medimmune)
Background Respiratory syncitial virus (RSV) is a highly contagious virus that is estimated to infect nearly all children by 3 years of age, and is the leading cause of serious lower respiratory tract
More informationSynagis. Synagis (palivizumab) Description. Section: Prescription Drugs Effective Date: July 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.20.04 Section: Prescription Drugs Effective Date: July 1, 2016 Subject: Synagis Page: 1 of 5 Last Review
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Synagis (palivizumab injection) Applicable* Medical Benefit x Effective: 8/15/18 Pharmacy- Formulary 1 Next Review: 6/19 Pharmacy- Formulary 2 Date of Origin: 6/05 Pharmacy- Formulary
More informationSynagis (Palivizumab) Drug Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Synagis (Palivizumab) Drug Prior Authorization Protocol This policy has been developed through review of medical
More informationAgreed by IDWP and VWP September Adopted by CHMP 13 October Start of public consultation 26 October 2016
1 2 3 13 October 2016 EMA/CHMP/360458/2016 Committee for Human Medicinal Products (CHMP) 4 5 6 7 8 Concept paper on preparation of a guideline on the evaluation of medicinal products indicated for the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Synagis) Reference Number: CP.PHAR.16 Effective Date: 08.01.09 Last Review Date: 05.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder
More informationMPE8 antibody hits the Achilles heel of the viruses Davide Corti
Press Release Publication in the scientific journal Nature: a human antibody that neutralizes 4 different viruses and has the potential to prevent and treat severe lower respiratory tract infections Discovery
More informationRecombinant, Insect Cell-Derived RSV Nanoparticle Vaccine
Recombinant, Insect Cell-Derived RSV Nanoparticle Vaccine Gregory Glenn Chief Medical Officer MVADS-Copenhagen 4 July 2012 1 Agenda for RSV Discussion Overview of Insect Cell Technology Respiratory Syncytial
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Synagis Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Synagis (palivizumab) Prime Therapeutics will review Prior Authorization Prior Authorization
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL HCN Exception/Other PALIVIZUMAB SYNAGIS 18564 Synagis may be covered during the RSV season from October 15, 2017 and March 31, 2018. If the PA is received prior to October 15, 2017,
More information1.0 Abstract. Palivizumab P Study Results Final
1.0 Abstract Title: Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
More informationMedImmune RSV Surveillance
MedImmune RSV Surveillance WHO Meeting of Mid-term Review of the RSV Surveillance Pilot Based on the Global Influenza Surveillance & Response System 18 20 December 2017 PAHO, Washington DC, USA Mark T.
More informationTrends in Chronologic Age and Infant Respiratory Syncytial Virus Hospitalization: an 8-Year Cohort Study
Adv Ther (2011) 28(3):195-201. DOI 10.1007/s12325-010-0106-6 ORIGINAL RESEARCH Trends in Chronologic Age and Infant Respiratory Syncytial Virus Hospitalization: an 8-Year Cohort Study Jon P. Fryzek William
More informationICH Considerations. Oncolytic Viruses September 17, 2009
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009 1. Introduction Oncolytic viruses
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Synagis) Reference Number: CP.HNMC.159 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationTexas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request
Form 1033 September 2017-E Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request About Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and serious
More informationICH CONSIDERATIONS Oncolytic Viruses
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ICH CONSIDERATIONS Oncolytic Viruses 20 November 2008 EMEA/CHMP/GTWP/607698/2008
More informationMedical Assistance Division Medicaid Drug Utilization Review Newsletter
Medical Assistance Division Medicaid Drug Utilization Review Newsletter Volume 8 Issue 4 4th Quarter 2014 Introduction American Academy of Pediatrics Issues New Guidance on Use of Synagis Felice R. Slaughter
More informationPassive Immunization Trials to Inform Vaccine Design
Passive Immunization Trials to Inform Vaccine Design Points for Consideration from deliberations held at the August 8, 2014 workshop Contents I. Introduction... 2 II. Types of trials... 2 1. Therapeutic
More informationRSV Vaccine Development Status Update
Photo: PATH/Doune Porter RSV Vaccine Development Status Update WHO RSV Surveillance Pilot 18-20 Dec 2017 Washington DC Deborah Higgins PATH Photo credit CENTER FOR VACCINE INNOVATION AND ACCESS PATH RSV
More informationtrial. Key trial data points:
February 23, 2015 ADMA Biologics Announces Positive Data on Primary and Secondary Endpoints from its Pivotal Phase III Clinical Trial for RI-002 at the AAAAI Medical Conference RAMSEY, N.J., Feb. 23, 2015
More informationDetection, Pathogenesis, and Therapy of Respiratory Syncytial
CLINICAL MICROBIOLOGY REVIEWS, Jan. 1988, p. 27-39 Vol. 1, No. 1 0893-8512/88/010027-13$02.00/0 Copyright C 1988, American Society for Microbiology Detection, Pathogenesis, and Therapy of Respiratory Syncytial
More informationSynagis (Pediatric RSV)
Synagis (Pediatric RSV) Forecast and Market Analysis to 2022 GDHC1135DFR / Published April 2013 Executive Summary Table below provides a summary of the key metrics in the pediatric RSV prophylactics market
More informationSobi to acquire Synagis US rights from AstraZeneca - Creates a platform for global growth. Investor Presentation l 13 November 2018
Sobi to acquire Synagis US rights from AstraZeneca - Creates a platform for global growth Investor Presentation l 13 November 2018 Forward looking statements In order to utilise the Safe Harbor provisions
More informationISCT Telegraft Column: Mesenchymal Stromal Cell (MSC) Product Characterization and Potency Assay Development
ISCT Telegraft Column: Mesenchymal Stromal Cell (MSC) Product Characterization and Potency Assay Development University of Wisconsin-Madison, Production Assistance for Cellular Therapies (PACT) Over the
More informationDrug Use Evaluation: Synagis (palivizumab) Summary of Findings:
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Drug Use Evaluation: Synagis (palivizumab) Summary
More information(For National Authority Use only)
Page 2 Medlmmune, Inc. Name ofactive Ingredient: PROTOCOL SYNOPSIS Title: A Phase II Study ofthe Safety, Tolerance,Phannacokinetics,and Effect on Viral Load in Tracheal Aspirates ofmedi-493, a Humanized
More informationNETSCC, HTA 26th July 2009
NETSCC, HTA 26 th July 2009 HTA 06/29/02 1 Title of the project: Palivizumab for immunoprophylaxis of respiratory syncitial virus (RSV) bronchiolitis in high risk infants, additional subgroup analysis
More informationVariable Resistance to Palivizumab in Cotton Rats by Respiratory Syncytial Virus Mutants
MAJOR ARTICLE Variable Resistance to Palivizumab in Cotton Rats by Respiratory Syncytial Virus Mutants Xiaodong Zhao, 1 Fu-Ping Chen, 1 A. George Megaw, 1 and Wayne M. Sullender 1,2 Departments of 1 Pediatrics
More informationRSV F Nanoparticle Vaccine: Update Gregory M. Glenn M.D., SVP R&D
RSV F Nanoparticle Vaccine: Update Gregory M. Glenn M.D., SVP R&D Summary of Findings in Recent Clinical Trials International Society of Vaccines October 26, 2014 1 www.novavax.com 2 The Problem with RSV
More informationReview Antibodies for prevention and treatment of respiratory syncytial virus infections in children
Antiviral Therapy 2012; 17:201 211 (doi: 10.3851/IMP2061) Review Antibodies for prevention and treatment of respiratory syncytial virus infections in children Bessey Geevarghese 1, Eric AF Simões 1,2,3
More informationPrevention of Serious Respiratory Syncytial Virus-Related Illness. II: Immunoprophylaxis
Adv Ther (2011) 28(2):110-125. DOI 10.1007/s12325-010-0101-y REVIEW Prevention of Serious Respiratory Syncytial Virus-Related Illness. II: Immunoprophylaxis Jessie R. Groothuis J. Michael Hoopes Val G.
More informationRequest for Prior Authorization for Synagis (palivizumab) Website Form Submit request via: Fax
Request for Prior Authorization for Synagis (palivizumab) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Synagis (palivizumab) require a Prior Authorization
More informationMonoclonal Antibodies for Treatment and Prevention of HIV-1 CROI Charles Boucher Erasmus MC
Monoclonal Antibodies for Treatment and Prevention of HIV-1 CROI 2018 Charles Boucher Erasmus MC Introduction: Human monoclonal antibodies Monoclonal Antibodies: Are identical immunoglobulins made by clone
More informationUnderstanding RSV Testing
TECHNICAL BULLETIN Vol. 1 No. 1, September 2004 Understanding RSV Testing 1 RSV Facts 2 3 Synagis and Its Effects On RSV Testing Choosing a Rapid RSV Test 4 5 6 BD Directigen RSV Technology: Two antibodies
More informationBIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE
The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting
More informationOxford Newborn Care Unit. Palivizumab (Synagis ) for RSV Infection Information for parents and carers
Oxford Newborn Care Unit Palivizumab (Synagis ) for RSV Infection Information for parents and carers page 2 Why have we been given this information? Your baby has been identified as being likely to benefit
More informationIndividual-Based Correlates of Protection
Module 8 Evaluating Immunological Correlates of Protection Session 3 Evaluating Correlates of Protection Using Individual, Population, and Titer-specific Approaches Ivan S.F. Chan, Ph.D. Merck Research
More informationPOSSIBILITIES FOR LABORATORY DIAGNOSIS OF RESPIRATORY SYNCYTIAL VIRUS
POSSIBILITIES FOR LABORATORY DIAGNOSIS OF RESPIRATORY SYNCYTIAL VIRUS T. Hadzhiolova, S. Pavlova, R. Kotseva Laboratory of Influenza and Acute Respiratory Diseases, National Center of Infectious and Parasitic
More informationPPTA Regulatory Workshop June 13, 2016
PPTA Regulatory Workshop June 13, 2016 DOROTY SCOTT Dr. Dorothy Scott is the Branch Chief for the Laboratory of Plasma Derivatives, in the Office of Blood Research and Review, CBER. Her group is responsible
More informationRespiratory syncytial virus (RSV) causes acute
Treatment of respiratory syncytial virus with palivizumab: a systematic review Jia Hu, Joan L. Robinson Edmonton, Canada 296 Background: Palivizumab has proven efficacy for prophylaxis of respiratory syncytial
More informationINFECTION RATES OF RESPIRATORY SYNCYTIAL VIRUS IN PEDIATRIC PATIENTS ATTENDING PHRA MONGKUTKLAO HOSPITAL, BANGKOK
INFECTION RATES OF RESPIRATORY SYNCYTIAL VIRUS IN PEDIATRIC PATIENTS ATTENDING PHRA MONGKUTKLAO HOSPITAL, BANGKOK SURANG TANTIVANICH, 0RALAK CHITYOTHIN and SAVANAT THARAVANIJ Department of Microbiology
More informationLinker p. 177 Helper Lipid p. 178 Delivery to Target Cells p. 180 Cell Entry p. 182 Receptor-Mediated Uptake p. 182 Endosomai Release p.
Overview of Regulatory Expectations for Introducing Novel Therapies into Clinical Trials Introduction p. 1 Roles of Regulatory Scientists p. 2 Product Development and Availability p. 2 Data Requirements
More informationJillian Redmond¹, Dr. Manoj Pastey² ¹BioResource Research ²College of Veterinary Medicine
Jillian Redmond¹, Dr. Manoj Pastey² ¹BioResource Research ²College of Veterinary Medicine Significant cause of mortality and morbidity Infants and elderly Causes most complications Immunocompromised More
More informationGene therapy. Findings by Alert
Gene therapy Published Mar 21, 2000 Version 1 Findings by Alert Research in gene therapy has increased dramatically during the past 15 years, particularly in the United States. The research has encompassed
More informationRSV vaccine: a changing landscape
RSV vaccine: a changing landscape Romina Libster Vaccinology 2018 Panama Gavilán 94 - C1406BAB - Capital Federal - Buenos Aires Argentina Tel.: (5411) 4634-0060/70 - Fax: int. 33 www.infant.org.ar Disclosures
More informationSTRATEGIC RSV INTERVENTION DEVELOPMENT ENTITY
STRATEGIC RSV INTERVENTION DEVELOPMENT ENTITY HRSV BACKGROUND UNMET CLINICAL NEEDS HRSV is the most common cause of lower respiratory tract infections among young children worldwide with also a major impact
More informationRegulatory considerations for initiating paediatric trials with RSV antivirals
Regulatory considerations for initiating paediatric trials with RSV antivirals Irmgard Eichler European Medicines Agency Expert meeting on RSV therapeutics March 2016 An agency of the European Union In
More informationICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008
European Medicines Agency October 2009 EMEA/CHMP/ICH/607698/2008 ICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008 TRANSMISSION TO INTERESTED
More informationA cost-benefit analysis of RSV prophylaxis in high-risk infants Schrand L M, Elliott J M, Ross M B, Bell E F, Mutnick A H
A cost-benefit analysis of RSV prophylaxis in high-risk infants Schrand L M, Elliott J M, Ross M B, Bell E F, Mutnick A H Record Status This is a critical abstract of an economic evaluation that meets
More informationImmunotherapy in myeloma
Immunotherapy in myeloma This Horizons Infosheet contains information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons Infosheet series provides information relating to
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
23 July 2015 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular
More information(51) Int Cl.: C07K 16/10 ( ) (56) References cited:
(19) TEPZZ 486Z B_T (11) EP 2 486 03 B1 (12) EUROPEAN PATENT SPECIFICATION (4) Date of publication and mention of the grant of the patent: 18.01.17 Bulletin 17/03 (21) Application number: 0978839.9 (22)
More informationRSV Prevention in Québec Season
RSV Prevention in Québec 2017 2018 Season Marc H. Lebel, MD, FRCPC Infectious-Diseases Service Dr. Marc Lebel Pediatrician infectiologist at the Sainte Justine Hospital since 1989 Founded the infectious
More informationARTICLE. Respiratory Syncytial Virus and Premature Infants Born at 32 Weeks Gestation or Earlier
ARTICLE Respiratory Syncytial Virus and Premature Infants Born at 32 Weeks Gestation or Earlier and Economic Implications of Prophylaxis Timothy P. Stevens, MD; Robert A. Sinkin, MD; Caroline B. Hall,
More informationReport to AHCA 06/2010
UTILITY OF CURRENT SURVEILLANCE SYSTEMS TO DETECT RESPIRATORY SYNCYTIAL VIRUS SEASONS AND IMPLICATIONS FOR IMMUNOPROPHYLAXIS Report to AHCA 6/21 Christian Hampp, PhD 1 Almut Winterstein, PhD 1, 2 1 Pharmaceutical
More informationASSESSING THE EFFICACY AND SAFETY OF NORMAL INTRAVENOUS IMMUNOGLOBULIN PRODUCTS FOR MARKETING AUTHORISATIONS
ASSESSING THE EFFICACY AND SAFETY OF NORMAL INTRAVENOUS IMMUNOGLOBULIN PRODUCTS FOR MARKETING AUTHORISATIONS Guideline Title Assessing the Efficacy and Safety of Normal Intravenous Immunoglobulin Products
More informationIn vivo Evaluation of Lassa virus Therapeutics. David Safronetz, Ph.D Public Health Agency of Canada
In vivo Evaluation of Lassa virus Therapeutics David Safronetz, Ph.D Public Health Agency of Canada Outline: Caveats Ribavirin Favipiravir or Ribavirin Favipiravir plus Ribavirin Antibody Treatments Promising
More informationBRIEF REPORT. Downloaded from by guest on 26 December 2018
BRIEF REPORT Anti G Protein Antibody Responses to Respiratory Syncytial Virus Infection or Vaccination Are Associated with Inhibition of G Protein CX3C-CX3CR1 Binding and Leukocyte Chemotaxis Jennifer
More informationRespiratory Syncytial Virus Prophylaxis Program Saskatchewan Protocol Season
Respiratory Syncytial Virus Prophylaxis Program Saskatchewan Protocol 2018-2019 Season Respiratory Syncytial Virus (RSV) is the most common cause of lower respiratory tract illness and hospitalization
More information1.0 Abstract. Title. Synagis liquid 50 mg, 100 mg for Intramuscular Injection: Special Investigation in Immunocompromised Children with Synagis
1.0 Abstract Title Synagis liquid 50 mg, 100 mg for Intramuscular Injection: Special Investigation in Immunocompromised Children with Synagis Keywords Palivizumab, respiratory syncytial virus, immunocompromised
More informationAntibody against Chikungunya virus (mrna-1944)
Antibody against Chikungunya virus (mrna-1944) Modality Program # Program Indication Preclinical development Phase 1 Phase 2 Phase 3 and commercial Moderna rights mrna-1944 Antibody against Chikungunya
More informationPioneering the Development of Safe and Effective Non-Viral Vectors and Processes for Human Gene Therapy and DNA Vaccination.
Pioneering the Development of Safe and Effective Non-Viral Vectors and Processes for Human Gene Therapy and DNA Vaccination. Founded 1999, Clague Hodgson, Ph.D. Chief Scientific Officer, VP, R&D, Jim Williams,
More informationComments of American Plasma Users Coalition (A-PLUS) To the Food and Drug Administration December 31, 2010
Comments of American Plasma Users Coalition (A-PLUS) To the Food and Drug Administration December 31, 2010 The American Plasma Users Coalition (A-PLUS) is a coalition of national patient advocacy organizations
More informationSupplemental Information
Supplemental Information DLA-matched bone marrow transplantation reverses the immunodeficiency of SCID dogs. Bone marrow transplantation studies were initiated with the goal of reversing the immunodeficiency
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE
More informationRegulation of advanced blood cell therapies
Regulation of advanced blood cell therapies www.pei.de Clinical trials using cell-based products Substantially manipulated cells and cells for non-homologous use Quality, safety and non-clinical aspects
More informationDevelopment of plasma therapies for emerging infectious diseases. Dr Glenn Smith Biological Science Section Scientific Evaluation Branch
Development of plasma therapies for emerging infectious diseases Dr Glenn Smith Biological Science Section Scientific Evaluation Branch June 2017 Therapeutic Goods Administration (TGA) A part of the Australian
More informationRE: Season for Respiratory Syncytial Virus Prophylaxis for High-Risk Infants
Ministr y o f He alth and Lon g-term Ca re Ontario Public Drug Programs Division Drug Programs Delivery Branch 3 rd Floor, 5700 Yonge Street Toronto ON M2M 4K5 Telephone: (416) 327-8109 Toll Free: 1-866-811-9893
More informationImmunotherapy in myeloma
Immunotherapy in myeloma Horizons Infosheet Clinical trials and novel drugs This Horizons Infosheet provides information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons
More informationGenitope Corporation. Summary of MyVax Personalized Immunotherapy Phase 3 Clinical Trial Results
Genitope Corporation Summary of MyVax Personalized Immunotherapy Phase 3 Clinical Trial Results Introduction In December 27, Genitope Corporation ( Genitope ) obtained data indicating that its pivotal
More informationCorporate Medical Policy
Corporate Medical Policy Respiratory Syncytial Virus Prophylaxis File Name: Origination: Last CAP Review: Next CAP Review: Last Review: respiratory_syncytial_virus_prophylaxis 1/1999 2/2018 2/2019 2/2018
More informationRespiratory Syncytial Virus Severe Morbidity and Mortality
Respiratory Syncytial Virus Severe Morbidity and Mortality Marika K Iwane, PhD MPH CDC Division of Viral Diseases Respiratory/Picornavirus Team PAHO-Panama City May 29, 2014 National Center for Immunization
More informationProphylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making Strutton D R, Stang P E
Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making Strutton D R, Stang P E Record Status This is a critical abstract of an economic
More informationEVALUATION OF THE SAFETY OF VETERINARY MEDICINAL PRODUCTS FOR THE TARGET ANIMALS
EVALUATION OF THE SAFETY OF VETERINARY MEDICINAL PRODUCTS FOR THE TARGET ANIMALS Guideline Title Evaluation of the Safety of Veterinary Medicinal Products for the Target Animals Legislative Basis Directive
More informationInvestigations in Immune Suppression for Monoclonal Antibody Therapeutics
Investigations in Immune Suppression for Monoclonal Antibody Therapeutics Vibha Jawa Principal Scientist AAPS NBC Meeting, May 2016 Clinical Immunology, Medical Sciences, Amgen Background Therapeutic proteins
More informationGrouping of Feline Calicivirus Field Isolates Using Monoclonal Antibodies
SHORT REPORT Grouping of Feline Calicivirus Field Isolates Using Monoclonal Antibodies Tomoko TAJIMA, Erika NAKATA, Yukinobu TOHYAI1), Kazuyo YURI2), Hiromi KATAE2), and Takeshi MIKAMI3) Department of
More informationDevelopment and challenges to monoclonal antibodies for passive immunization
Development and challenges to monoclonal antibodies for passive immunization Erin Sparrow 21 June 2017 1 A brief history of serum derived passive immunization Concept developed by von Behring & Kitasato
More informationCHAPTER 24. Immunology
CHAPTER 24 Diagnostic i Microbiology and Immunology Growth-Dependent Diagnostic Methods Isolation of Pathogens from Clinical Specimens Proper sampling and culture of a suspected pathogen is the most reliable
More informationSuppression of Polyclonal Immunoglobulin Production by M-proteins Shows Isotype Specificity
274 Annals of Clinical & Laboratory Science, vol. 31, no. 3, 2001 Suppression of Polyclonal Immunoglobulin Production by M-proteins Shows Isotype Specificity Liang Wang and David C. Young Department of
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
1 2 3 15 November 2012 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous
More informationArsanis, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationKey words: respiratory syncytial virus; RSV; ribavirin; IVIG; hematopoietic stem cell transplant; lung transplant; immunocompromised
2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Transplant Infectious Disease, ISSN 1398-2273 Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory
More informationChapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology
Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing
More information1. Immunization. What is Immunization? 12/9/2016. Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology
Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing
More informationto those attained in animals with pulmonary or systemic infections. However, the vaccinated cotton rats developed a
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1986, p. 197-202 0095-1137/86/080197-06$02.00/0 Copyright C 1986, American Society for Microbiology Vol. 24, No. 2 Dissociation between Serum Neutralizing and Glycoprotein
More informationSYNAGIS (palivizumab) injection, for intramuscular use Initial U.S. Approval: 1998
US-10672 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNAGIS safely and effectively. See full prescribing information for SYNAGIS. SYNAGIS (palivizumab)
More informationVirus vs. virus: adenovirus vectored vaccine to defeat respiratory syncytial virus
Editorial Page 1 of 5 Virus vs. virus: adenovirus vectored vaccine to defeat respiratory syncytial virus Alessandra Vitelli 1, Alfredo Nicosia 1,2,3 1 ReiThera Srl, Rome, Italy; 2 CEINGE, Naples, Italy;
More information1 R01 AI VMD HALFORD, W
1 R01 AI104935-01 2 VMD 1R01AI104935-01 ILLIAM CRITIQUE 1: Significance: 5 Investigator(s): 2 Innovation: 5 Approach: 8 Environment: 2 Overall Impact: This application proposes to develop a recombinant
More informationPROCEEDINGS MANAGED CARE AND SPECIALTY PHARMACY IMPLICATIONS OF RSV MANAGEMENT * Sheldon J. Rich, RPh, PhD, and Nick Calla, RPh ABSTRACT
MANAGED CARE AND SPECIALTY PHARMACY IMPLICATIONS OF RSV MANAGEMENT * Sheldon J. Rich, RPh, PhD, and Nick Calla, RPh ABSTRACT Respiratory syncytial virus (RSV) is the leading cause of hospitalization among
More informationSCM Lifescience COMPANY PROFILE BUSINESS AREAS. [Address] 310, 366 Seohae-daero, Jung-gu, Incheon, Korea [Website]
SCM Lifescience [Address] 310, 366 Seohae-daero, Jung-gu, Incheon, Korea 22332 [Website] http://www.scmlifescience.com COMPANY PROFILE [Industry] SCM Lifescience is a research-based biopharmaceutical company
More informationANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1999, p Vol. 43, No. 5. Copyright 1999, American Society for Microbiology. All Rights Reserved.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1999, p. 1183 1188 Vol. 43, No. 5 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Safety and Pharmacokinetics of
More information